Affinity Investment Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$833K Buy
13,730
+198
+1% +$11.5K 0.52% 66
2025
Q4
$730K Sell
13,532
-130
-1% -$6.25K 0.48% 71
2025
Q3
$616K Sell
13,662
-360
-3% -$16.8K 0.42% 76
2025
Q2
$649K Sell
14,022
-470
-3% -$23.1K 0.49% 73
2025
Q1
$884K Sell
14,492
-132
-0.9% -$7.69K 0.72% 49
2024
Q4
$827K Sell
14,624
-3,568
-20% -$199K 0.69% 55
2024
Q3
$941K Buy
18,192
+117
+0.6% +$5.49K 0.65% 56
2024
Q2
$751K Sell
18,075
-148
-0.8% -$6.62K 0.56% 64
2024
Q1
$988K Sell
18,223
-42
-0.2% -$2.14K 0.72% 51
2023
Q4
$937K Sell
18,265
-2,140
-10% -$112K 0.64% 51
2023
Q3
$1.18M Sell
20,405
-583
-3% -$35.7K 0.76% 39
2023
Q2
$1.34M Sell
20,988
-4,934
-19% -$331K 0.78% 41
2023
Q1
$1.8M Sell
25,922
-16,594
-39% -$1.17M 0.96% 23
2022
Q4
$3.06M Hold
42,516
1.41% 12
2022
Q3
$3.02M Sell
42,516
-554
-1% -$40.2K 1.57% 9
2022
Q2
$3.32M Sell
43,070
-446
-1% -$34K 1.62% 10
2022
Q1
$3.18M Sell
43,516
-302
-0.7% -$20.3K 1.3% 11
2021
Q4
$2.73M Sell
43,818
-4,090
-9% -$240K 1.1% 27
2021
Q3
$2.83M Sell
47,908
-349
-0.7% -$23K 1.27% 19
2021
Q2
$3.23M Sell
48,257
-18,910
-28% -$1.23M 1.46% 12
2021
Q1
$4.24M Sell
67,167
-1,600
-2% -$99.5K 1.55% 17
2020
Q4
$4.27M Sell
68,767
-2,811
-4% -$173K 1.72% 12
2020
Q3
$4.32M Buy
71,578
+3,739
+6% +$225K 1.89% 12
2020
Q2
$3.99M Sell
67,839
-9,016
-12% -$539K 1.9% 11
2020
Q1
$4.28M Sell
76,855
-1,672
-2% -$102K 2.18% 11
2019
Q4
$5.04M Sell
78,527
-14,376
-15% -$823K 1.83% 13
2019
Q3
$4.71M Sell
92,903
-3,344
-3% -$157K 1.48% 28
2019
Q2
$4.37M Sell
96,247
-60,110
-38% -$2.8M 1.25% 38
2019
Q1
$7.46M Sell
156,357
-43,027
-22% -$2.14M 1.53% 28
2018
Q4
$10.4M Sell
199,384
-17,750
-8% -$954K 1.81% 18
2018
Q3
$13.5M Buy
+217,134
New +$12.9M 1.78% 18
2016
Q3
Sell
-4,492
Closed -$330K 154
2016
Q2
$330K Hold
4,492
0.02% 128
2016
Q1
$287K Buy
+4,492
New +$283K 0.03% 130

Other funds holding BMY

Affinity Investment Advisors's BMY Position: Q1 2026 in Review

Affinity Investment Advisors increased its Bristol-Myers Squibb (BMY) stake by 1.5% in Q1 2026, buying an estimated $11.5K and bringing the position to 13,730 shares worth $833K. The position accounts for 0.52% of the portfolio, ranked #66.

Affinity Investment Advisors first reported a position in BMY in Q1 2016 and has held it in 33 quarters since. The position peaked at $13.5M in Q3 2018. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Affinity Investment Advisors held 13,730 shares of Bristol-Myers Squibb worth $833K as of Q1 2026.
  • Affinity Investment Advisors bought 198 Bristol-Myers Squibb shares in Q1 2026, an estimated $11.5K.
  • Bristol-Myers Squibb made up 0.52% of Affinity Investment Advisors's portfolio in Q1 2026, its #66 holding.
  • Affinity Investment Advisors first reported a position in Bristol-Myers Squibb in Q1 2016 and has held it in 33 quarters since.
  • Affinity Investment Advisors's Bristol-Myers Squibb position peaked at $13.5M in Q3 2018.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Affinity Investment Advisors's 13F filing for Q1 2026, filed 14 May 2026.